Having been short of good news, Telix says the first stage of its phase III prostate cancer therapeutic trial has hit its desired safety and dosage goals. Telix today said the candidate, TLX591-Tx , ...

Telix Pharmaceuticals has announced positive early-stage results from its global phase 3 trial of TLX591, an experimental treatment for advanced prostate cancer. The initial phase of the trial, ...

Tremendous activity in recent months, including receipt of Japanese marketing approval, the fifth parallel U.S. trial ...

FDA approved Pylarify TruVu, a higher-radioactivity-concentration formulation of piflufolastat F 18 designed to increase batch size and distribution efficiency while maintaining the established ...

Manufacturing optimization is projected to expand batch output by ~50%, improving supply reliability and supporting higher-throughput PSMA PET imaging services. Increased radioactivity extends shelf ...

Prostate cancer is one of the most common cancers affecting men around the world. In many countries, including Germany, it is the most frequently diagnosed cancer in men. Each year, about 65,000 men ...

Profound Medical Corp. (NASDAQ:PROF) Q4 2025 Earnings Call Transcript March 6, 2026 Operator: Good day, and thank you for ...

Metastatic prostate cancer is currently associated with high morbidity and mortality rates. In addition, patients respond very differently to standard treatments such as hormone therapy or radiation ...

New formulation of its widely-used U.S. market-leading PSMA PET imaging agent combines the diagnostic performance of PYLARIFY ® (piflufolastat F 18) with the potential for larger ...

An investigational approach to diagnosis of prostate cancer uses sound waves to extract "bubbles of information" from cells. ...

Prostate cancer is the most common cancer in men throughout the United States. Most men do not realize they have cancer due ...

Oxybutynin significantly reduced hot flash frequency and severity compared with placebo among men with prostate cancer ...